Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001964306-24-000382
Filing Date
2024-10-17
Accepted
2024-10-17 16:26:39
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 2934
  Complete submission text file 0001964306-24-000382.txt   4490
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Fust Matthew K (Reporting) CIK: 0001397266 (see all company filings)

Type: 144

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Subject) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-41802 | Film No.: 241377879
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)